GE Healthcare has finalized a deal with Thermo Fisher Scientific  to acquire its HyClone cell culture media and sera, and gene modulation and magnetic beads businesses. Reportedly, this transaction will allow GE   to expand its offering of end-to-end technologies for cell biology research, cell therapy and for the discovery and manufacturing of new medicines, vaccines and diagnostics in its growing Life Sciences business. Transaction is expected to be completed in the first part of 2014.